The major cause of COVID-19 patient death is inflammation-related complication, and ORF3a is the major inflammation inducer. Targeting ORF3a can be a effective way to reduce COVID-19-related patient death.
What it does
We are screening drugs that reduce ORF3a protein levels, leading to decreased inflammation.
How I built it
Construct ORF3a-GFP-reporter lines and perform drug screening.
Challenges I ran into
Scheduling and coordinate with different people during the lockdown.
Accomplishments that I'm proud of
We have the platform established for the large-scale drug screening.
What I learned
Together, we will win the battle with COVID-19!
What's next for Targeting ORF-3a mediated inflammation in COVID-19 patients
Screen and optimize the lead compound.